GH Research PLC (GHRS) research
GH Research PLC- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $22.94
- As of
GH Research PLC (GHRS): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-11.
As of . Source: SEC EDGAR filings for GHRS. Method and limitations.
Share the GHRS intelligence card
See the full GHRS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GHRS on one page. Preview it with sample data, then open it live with a free account.
Preview the GHRS dossierActive signals for GHRS
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 66% of GHRS (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +227% to GHRS (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in GHRS
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 25.6%, EPS $-0.23 vs $-0.3091 estimate
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +217% to GHRS (2026Q1)
FREE, NO ACCOUNT
Every signal on GHRS, as it fires
You are seeing 5 of 10 signals recorded on GHRS since 2026-06-18.
The five above landed across 3 days. The other 5 were recorded on 2 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GHRS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP G3855L106 · 2026Q2 | $8.7M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP G3855L106 · 2026Q2 | $2.3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP G3855L106 · 2026Q2 | $1.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP G3855L106 · 2026Q2 | $681K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GHRS
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
GHRS against its peers
GHRS's return on equity of -17.3% ranks in the 81st percentile of 17 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | GHRS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 118M | n/a | 14 |
| Operating margin | n/a | -148.6% | n/a | 15 |
| Net margin | n/a | -106.4% | n/a | 15 |
| Return on equity | -17.3% | -54.1% | 81 | 17 |
Peers (21): RAPP, NTLA, TSHA, ABSI, SNDX, FBRX, IMCR, STOK, NBTX, ANAB, AVBP, MAZE, TYRA, INBX, VIR, NVAX, ZBIO, RARE, SEPN, CMPS, DRTS. Left out: KLRA (no annual filing), COAG (no annual filing), KALV (no annual filing), AAPG (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (GHRS: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more GHRS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to GHRSand get the insider, 13F, options, and confluence read in one view.